Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619123 | 0.82 | TP53 (0.46) | RAB9ANPC1TP53KDM4EHSD17B10 | |
| SCHEMBL2668397 | 0.80 | KDM4E (0.38) | PRMT5WDR77TP53KDM4ESMN1; SMN2 | |
| SCHEMBL1619405 | 0.80 | KDM4E (0.49) | RAB9ANPC1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL1618951 | 0.80 | KDM4E (0.39) | RAB9ANPC1PRMT5WDR77TP53 | |
| SCHEMBL1617826 | 0.79 | HPGD (0.55) | RAB9ANPC1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL1619404 | 0.79 | ALDH1A1 (0.49) | RAB9ANPC1TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL1619269 | 0.79 | KMT2A (0.49) | RAB9ANPC1TP53KDM4ESMN1; SMN2 | |
| SCHEMBL1619379 | 0.79 | KDM4E (0.41) | RAB9ANPC1TP53KDM4ETDP1 | |
| SCHEMBL1619203 | 0.78 | CHRM1 (0.43) | RAB9ANPC1KDM4ETDP1MEN1 | |
| SCHEMBL1619459 | 0.77 | SCN9A (0.52) | SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | claimed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | claimed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | BIAN HAIYAN | 2009-08-13 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-7531671-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| EP-1951706-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007053662-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099936-A1 | Dihydroisoindolones As Allosteric Modulators Of Glucokinase | GCK, GCKR, GPR119 | RAB9A 3049/4885NPC1 2844/4885PRMT5 2309/4885 |
| US-20090202525-A1 | DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | GCK, GCKR, GPR119 | RAB9A 3088/4885NPC1 2849/4885PRMT5 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.